Deguelin inhibits the proliferation of human multiple myeloma cells by inducing apoptosis and G2/M cell cycle arrest: Involvement of Akt and p38 MAPK signalling pathway

Sun, Kening; Chen, Ping; Zhang, Liang; Lu, Zhidong; Jin, Qunhua

doi:10.2478/acph-2024-0003

Abstract

Deguelin exhibits antiproliferative activity against various cancer cell types. Previous studies have reported that deguelin exhibits pro-apoptotic activity against human cancer cells. The current study aimed at further elaborating the anticancer effects of deguelin against multiple myeloma cells. Cell growth estimations were made through MTT assay. Phase contrast microscopy was used for the analysis of the viability of multiple myeloma cells. Colony formation from multiple myeloma cells was studied using a clonogenic assay. Antioxidative assays for determining levels of glutathione (GSH) and superoxide dismutase (SOD) were carried out after treating multiple myeloma cells with deguelin. The apoptosis of multiple myeloma cells was studied using AO/EB and Annexin V-FITC/PI staining methods. Multiple myeloma cell cycle analysis was performed through flow cytometry. mRNA expression levels were depicted using qRT-PCR. Migration and invasion of multiple myeloma cells were determined with the wound-healing and transwell assays, respectively. Deguelin specifically inhibited the multiple myeloma cell growth while the normal plasma cells were minimally affected. Multiple myeloma cells when treated with deguelin exhibited remarkably lower viability and colony-forming ability. Multiple myeloma cells treated with deguelin produced more SOD and had higher GSH levels. The multiple myeloma cell growth, migration, and invasion were significantly declined by in vitro administration of deguelin. In conclusion, deguelin treatment, when applied in vitro, induced apoptotic cell death and resulted in mitotic cessation at the G2/M phase through modulation of cell cycle regulatory mRNAs in multiple myeloma cells.

References

S. Gandolfi, J. P. Laubach, T. Hideshima, D. Chauhan, K. C. Anderson and P. G. Richardson, The proteasome and proteasome inhibitors in multiple myeloma, Cancer Metastasis Rev. 36(4) (2017) 561–584; https://doi.org/10.1007/s10555-017-9707-8
Search in Google Scholar Back to article
M. Diaz-delCastillo, A. D. Chantry, M. A. Lawson and A. M. Heegaard, Multiple myeloma – A painful disease of the bone marrow, Semin. Cell Dev. Biol. 112 (2021) 49–58; https://doi.org/10.1016/j.semcdb.2020.10.006
Search in Google Scholar Back to article
E. S. Ring, M. A. Lawson, J. A. Snowden, I. Jolley and A. D. Chantry, New agents in the treatment of myeloma bone disease, Calcif. Tissue Int. 102(2) (2018) 196–209; https://doi.org/10.1007/s00223-017-0351-7
Search in Google Scholar Back to article
F. Marofi, S. Tahmasebi, H. S. Rahman, D. Kaigorodov, A. Markov, A. V. Yumashev, N. Shomali, M. S. Chartrand, Y. Pathak, R. N. Mohammed, M. Jarahian, R. Motavalli and F. Motavalli Khiavi, Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism, Stem Cell Res. Ther. 12(1) (2021) Article ID 217 (21 pages); https://doi.org/10.1186/s13287-021-02283-z
Search in Google Scholar Back to article
B. Noel, S. K. Singh, J. W. Lillard, Jr. and R. Singh, Role of natural compounds in preventing and treating breast cancer, Front Biosci. 12(1) (2020) 137–160; https://doi.org/10.2741/S544
Search in Google Scholar Back to article
M. Ezzati, B. Yousefi, K. Velaei and A. Safa, A review on anti-cancer properties of quercetin in breast cancer, Life Sci. 248 (2020) Article ID 117463; https://doi.org/10.1016/j.lfs.2020.117463
Search in Google Scholar Back to article
Y. Wang, W. Ma and W. Zheng, Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention, Mol. Clin. Oncol. 1(2) (2013) 215–219; https://doi.org/10.3892/mco.2012.36
Search in Google Scholar Back to article
Y. Baba and Y. Kato, Deguelin, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 10; https://doi.org/10.1016/j.ebiom.2017.11.010
Search in Google Scholar Back to article
X. D. Xu, Y. Zhao, M. Zhang, R. Z. He, X. H. Shi, X. J. Guo, C. J. Shi, F. Peng, M. Wang, M. Shen, X. Wang, X. Li and R. Y. Qin, Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin, Int. J. Mol. Sci. 18(2) (2017) Article ID 370 (13 pages); https://doi.org/10.3390/ijms18020370
Search in Google Scholar Back to article
X. H. Peng, P. Karna, R. M. O’Regan, X. Liu, R. Naithani, R. M. Moriarty, W. C. Wood, H. Y. Lee and L. Yang, Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells, Mol. Pharmacol. 71(1) (2007) 101–111; https://doi.org/10.1124/mol.106.027367
Search in Google Scholar Back to article
G. Murillo, X. Peng, K. E. Torres and R. G. Mehta, Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway, Cancer Prev. Res. 2(11) (2009) 942–950; https://doi.org/10.1158/1940-6207.CAPR-08-0232
Search in Google Scholar Back to article
T. Yi, H. Li, X. Wang and Z. Wu, Enhancement radiosensitization of breast cancer cells by deguelin, Cancer Biother. Radiopharm. 23(3) (2008) 355–362; https://doi.org/10.1089/cbr.2007.0452
Search in Google Scholar Back to article
E. B. Kurutas, The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state, Nutr. J. 15(1) (2016) Article ID 71 (22 pages); https://doi.org/10.1186/s12937-016-0186-5
Search in Google Scholar Back to article
K. A. Kang, M. J. Piao, Y. S. Ryu, Y. J. Hyun, J. E. Park, K. Shilnikova, A. X. Zhen, H. K. Kang, Y. S. Koh, Y. J. Jeong and J. W. Hyun, Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells, Int. J. Oncol. 51(4) (2017) 1169–1178; https://doi.org/10.3892/ijo.2017.4091
Search in Google Scholar Back to article
S. Deng, M. K. Shanmugam, A. P. Kumar, C. T. Yap, G. Sethi and A. Bishayee, Targeting autophagy using natural compounds for cancer prevention and therapy, Cancer 125(8) (2019) 1228–1246; https://doi.org/10.1002/cncr.31978
Search in Google Scholar Back to article
A. Lichota and K. Gwozdzinski, Anticancer activity of natural compounds from plant and marine environment, Int. J. Mol. Sci. 19(11) (2018); Article ID 3533 (38 pages); https://doi.org/10.3390/ijms19113533
Search in Google Scholar Back to article
A. J. Robles, S. Cai, R. H. Cichewicz and S. L. Mooberry, Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer, Breast Cancer Res. Treat. 157(3) (2016) 475–488; https://doi.org/10.1007/s10549-016-3841-9
Search in Google Scholar Back to article
L. Chen, K. Jiang, H. Chen, Y. Tang, X. Zhou, Y. Tan, Y. Yuan, Q. Xiao and K. Ding, Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway, Cancer Manag. Res. 11 (2019) 95–105; https://doi.org/10.2147/CMAR.S169476
Search in Google Scholar Back to article
W. Kang, X. Zheng, P. Wang and S. Guo, Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro, Int. J. Mol. Med. 41(6) (2018) 3157–3166; https://doi.org/10.3892/ijmm.2018.3532
Search in Google Scholar Back to article
K. Liu, M. Zheng, R. Lu, J. Du, Q. Zhao, Z. Li, Y. Li and S. Zhang, The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review, Cancer Cell Int. 20 (2020) Article ID 213 (16 pages); https://doi.org/10.1186/s12935-020-01304-w
Search in Google Scholar Back to article
S. Dalton, Cell cycle regulation of the human cdc2 gene, Embo J. 11(5) (1992) 1797–1804; https://doi.org/10.1002/j.1460-2075.1992.tb05231.x
Search in Google Scholar Back to article
X. Yu, Q. Liang, W. Liu, L. Zhou, W. Li and H. Liu, Deguelin, an aurora B Kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 100–111; https://doi.org/10.1016/j.ebiom.2017.10.030
Search in Google Scholar Back to article
W. Li, X. Yu, X. Ma, L. Xie, Z. Xia, L. Liu, J. Wang, H. Zhou, X. Zhou, Y. Yang and H. Liu, Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway, Cell Signal. 50 (2018) 131–141; https://doi.org/10.1016/j.cellsig.2018.07.001
Search in Google Scholar Back to article
S. R. Boreddy and S. K. Srivastava, Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model, Oncogene 32(34) (2013) 3980–3991; https://doi.org/10.1038/onc.2012.413
Search in Google Scholar Back to article
J. Yang, J. Nie, X. Ma, Y. Wei, Y. Peng and X. Wei, Targeting PI3K in cancer: mechanisms and advances in clinical trials, Mol. Cancer 18(1) (2019) Article ID 26 (28 pages); https://doi.org/10.1186/s12943-019-0954-x
Search in Google Scholar Back to article
B. D. Manning and L. C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129(7) (2007) 1261–1274; https://doi.org/10.1016/j.cell.2007.06.009
Search in Google Scholar Back to article
G. M. Nitulescu, M. Van De Venter, G. Nitulescu, A. Ungurianu, P. Juzenas, Q. Peng, O. T. Olaru, D. Gradinaru, A. Tsatsakis, D. Tsoukalas, D. A. Spandidos and D. Margina, The Akt pathway in oncology therapy and beyond (Review), Int. J. Oncol. 53(6) (2018) 2319–2331; https://doi.org/10.3892/ijo.2018.4597
Search in Google Scholar Back to article

Deguelin inhibits the proliferation of human multiple myeloma cells by inducing apoptosis and G2/M cell cycle arrest: Involvement of Akt and p38 MAPK signalling pathway

Abstract

Paradigm

My account